Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18937660 | 1.00 | CYP19A1 (0.33) | CYP19A1DEGS1 | |
| SCHEMBL18937453 | 1.00 | CYP19A1 (0.33) | CYP19A1DEGS1 | |
| SCHEMBL10136548 | 0.86 | FFAR4 (0.33) | — | |
| SCHEMBL18937728 | 0.82 | MEN1 (0.33) | — | |
| SCHEMBL74849 | 0.82 | DEGS1 (0.36) | DEGS1 | |
| SCHEMBL4546673 | 0.82 | — | — | |
| SCHEMBL10121187 | 0.82 | DEGS1 (0.36) | DEGS1 | |
| SCHEMBL20429067 | 0.81 | CYP19A1 (0.40) | CYP19A1DEGS1 | |
| SCHEMBL25143837 | 0.79 | — | — | |
| SCHEMBL18377810 | 0.79 | CYP19A1 (0.33) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023283488-A9 | CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF | CZ BIOHUB SF, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023283488-A2 | CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-10787454-B2 | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | BIAL—BioTech Investments, Inc. (PT) | 2020-09-29 | — | — | US | disclosed |
| US-20190119283-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-04-25 | — | — | US | disclosed |
| US-9920061-B2 | Imidazo[1,5-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170349599-A1 | IMIDAZO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-07 | — | — | US | disclosed |
| EP-2400846-B1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119283-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, GBA2 | CYP19A1 3698/4885DEGS1 3452/4885 |
| US-10787454-B2 | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | GBA1, GAA, GBA2 | CYP19A1 3698/4885DEGS1 3452/4885 |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | CYP19A1 3155/4885DEGS1 3937/4885 |
| US-20170349599-A1 | IMIDAZO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, GBA2 | CYP19A1 3698/4885DEGS1 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.